drugset / Trial / NCT02040415

Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients

NCT02040415

Phase 3 Completed 242 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to eperisone HCl in efficacy and safety.

Timeline

Start
2014-03
Primary completion
2014-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Eperisone Small molecule 50 mg
Subject Eperisone Small molecule 75 mg

Indications

No indication recorded.